• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Biocon: Biosimilars Company Analysis Product Image

Biocon: Biosimilars Company Analysis

  • Published: July 2012
  • Region: Global
  • 41 Pages
  • Datamonitor

Analysis of Biocon’s corporate history, corporate relationships, biosimilars development pipeline, and Datamonitor's evaluation of the company's strategy and key strengths, weaknesses, opportunities and threats.

This analysis evaluates the company’s strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company’s biosimilars portfolio, including analysis of key product profiles, examining key drivers and resistors to development, market sizing, specifics of development such as clinical trials (where available) for each key biosimilar molecule in development.

Scope

- Strategic insight into the key strategies that have shaped the company's progress and/or will define its outlook going forward.
- Provides an indication of how biosimilars fit into the wider company context, and a history of deals & alliances.

Highlights

- Biocon's aspirations of expanding from its strong position in the Indian diabetes market were dashed when Pfizer pulled out of an insulin biosimilars deal in March 2012. It remains to be seen to what extent Biocon can continue development alone, or whether a replacement READ MORE >

ABOUT THIS REPORT
- Chapter structure
- - Strategic insight
- - Product analysis
- - Operating performance
- - Company introduction

- Data sourcing
- - Analyst consensus

- PharmaVitae Explorer database

EXECUTIVE SUMMARY
- Biocon biosimilars overview
- Biocon biosimilars SWOT analysis
- - Strengths
- - Weaknesses
- - Opportunities
- - Threats

STRATEGIC INSIGHT
- Biocon to extend existing alliances and seek out new partners
- Biocon to leverage in-house end-to-end development capabilities

KEY PRODUCTS
- Overview
- Biocon biosimilar portfolio
- Basalog, insulin aspart, and insulin lispro
- - Overview
- - Insulin glargine, lispro, and aspart global market size
- - Key competitors
- - Biocon biosimilar development

- Insugen (human insulin)
- - Overview
- - Insulin human market size
- - Key competitors
- - Biocon biosimilar development

- Erypo (epoetin alfa)
- - Overview and market size
- - Key competitors

- NUFIL and pegfilgrastim
- - Overview
- - Filgrastim and pegfilgrastim market size
- - Key competitors

- Bmab-200 (trastuzumab)
- - Overview
- - Trastuzumab market size
- - Key competitors
- - Biocon biosimilar development

CORPORATE STRUCTURE

- Background
- Key corporate developments and company structure
- Deals and alliances
- - Biocon and Pfizer conclude partnership
- - Biocon and Mylan
- - Biocon’s other biosimilar-related deals

- Recent developments

APPENDIX

- References
- - Datamonitor reports

- Exchange rates

TABLES

Table: Biocon – biosimilar and novel biologic portfolio
Table: Forecasted lispro, aspart, and glargine insulin sales in the seven major markets and ROW ($m), 2011–16
Table: Biosimilar insulin aspart, insulin glargine, and insulin lispro products currently launched or in development
Table: Biocon – biosimilar insulin glargine clinical trials
Table: Forecasted human insulin sales in the seven major markets and ROW ($m), 2011–16
Table: Biosimilar human insulin products currently launched or in development
Table: Biocon – biosimilar human insulin clinical trials
Table: Forecasted epoetin sales in the seven major markets and ROW ($m), 2011–16
Table: Biocon – pipeline and marketed biosimilar epoetin drugs
Table: Forecasted filgrastim and pegfilgrastim sales ($m), 2011–16
Table: Biocon – pipeline and marketed biosimilar filgrastim and pegfilgrastim drugs
Table: Forecasted trastuzumab sales in the seven major markets and ROW ($m), 2011–16
Table: Biosimilar trastuzumab drugs, 2012
Table: Biocon – biosimilar trastuzumab clinical trials
Table: Biocon – biosimilar related deal activities
Table: Exchange rates, 2012

FIGURES

Figure: The PharmaVitae Explorer
Figure: Biocon biosimilars overview
Figure: Biocon SWOT analysis
Figure: Biocon biosimilars development capabilities
Figure: Biocon – corporate structure

Note: Product cover images may vary from those shown

RELATED PRODUCTS